Replication of colonic crohn's disease mucosal Escherichia coli isolates within macrophages and their susceptibility to antibiotics

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 2, 2008, Pages 427-434

  Subramanian, Sreedhar ^a   Roberts, Carol L ^a   Hart, C Anthony ^a   Martin, Helen M ^a   Edwards, Steve W ^a   Rhodes, Jonathan M ^a   Campbell, Barry J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; RIFAMPICIN; SULFAMETHOXAZOLE; TETRACYCLINE; TRIMETHOPRIM;

ANIMAL CELL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CELL VACUOLE; COLON CROHN DISEASE; CONTROLLED STUDY; CYTOLYSIS; DRUG BLOOD LEVEL; ELECTRON MICROSCOPY; ESCHERICHIA COLI; ESCHERICHIA COLI K 12; HUMAN; HUMAN CELL; ILEUM; LYSOSOME; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PATHOGENESIS; PHAGOSOME; PRIORITY JOURNAL; STOMACH MUCOSA;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; CELLS, CULTURED; COLON; CROHN DISEASE; CULTURE MEDIA; ESCHERICHIA COLI; HUMANS; MACROPHAGES; MICE; MICROBIAL SENSITIVITY TESTS; MONOCYTES; MUCOUS MEMBRANE;

EID: 38649143210     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00375-07     Document Type: Article

References (71)

1. Aderem, A. 2003. Phagocytosis and the inflammatory response. J. Infect. Dis. 187(Suppl. 2):S340-S345.
2. Agalar, C., S. Usubutun, and R. Turkyilmaz. 1999. Ciprofloxacin and rifampicin versus doxycycline and rifampicin in the treatment of brucellosis. Eur. J. Clin. Microbiol. Infect. Dis. 18:535-538.
3. Allen, L. A. 2003. Mechanisms of pathogenesis: evasion of killing by polymorphonuclear leukocytes. Microbes Infect. 5:1329-1335.
4. Alpuche-Aranda, C. M., E. L. Racoosin, J. A. Swanson, and S. I. Miller. 1994. Salmonella stimulate macrophage macropinocytosis and persist within spacious phagosomes. J. Exp. Med. 179:601-608.
5. Amsden, G. W. 2001. Advanced-generation macrolides: tissue-directed antibiotics. Int. J. Antimicrob. Agents 18(Suppl. 1):S11-S15.
6. Arnold, G. L., M. R. Beaves, V. O. Pryjdun, and W. J. Mook. 2002. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm. Bowel Dis. 8:10-15.
7. Baca, O. G., Y. P. Li, and H. Kumar. 1994. Survival of the Q. fever agent Coxiella burnetii in the phagolysosome. Trends Microbiol. 2:476-480.
8. Bringer, M. A., A. L. Glasser, C. H. Tung, S. Meresse, and A. Darfeuille-Michaud. 2006. The Crohn's disease-associated adherent-invasive Escherichia coli strain LF82 replicates in mature phagolysosomes within 1774 macrophages. Cell Microbiol. 8:471-484.
9. Cafini, F., L. Alou, D. Sevillano, E. Valero, and J. Prieto. 2004. Bactericidal activity of moxifloxacin against multidrug-resistant Streptococcus pneumoniae at clinically achievable serum and epithelial lining fluid concentrations compared with three other antimicrobials. Int. J. Antimicrob. Agents 24:334-338.
10. Cartun, R. W., H. J. Van Kruiningen, C. A. Pedersen, and M. M. Berman. 1993. An immunocytochemical search for infectious agents in Crohn's disease. Mod. Pathol. 6:212-219.
11. Clermont, O., S. Bonacorsi, and E. Bingen. 2000. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl. Environ. Microbiol. 66:4555-4558.
12. Couper, R., J. Kapelushnik, and A. M. Griffiths. 1991. Neutrophil dysfunction in glycogen storage disease Ib: association with Crohn's-like colitis. Gastroenterology 100:549-554.
13. Darfeuille-Michaud, A., J. Boudeau, P. Bulois, C. Neut, A. L. Glasser, N. Barnich, M. A. Bringer, A. Swidsinski, L. Beaugerie, and J. F. Colombel. 2004. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127:412-421.
14. Darfeuille-Michaud, A., C. Neut, N. Barnich, E. Lederman, P. Di Martino, P. Desreumaux, L. Gambiez, B. Joly, A. Cortot, and J. F. Colombel. 1998. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 115:1405-1413.
15. DeLeo, F. R. 2004. Modulation of phagocyte apoptosis by bacterial pathogens. Apoptosis 9:399-413.
16. D'Haens, G. R., K. Geboes, M. Peeters, F. Baert, F. Penninckx, and P. Rutgeerts. 1998. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114:262-267.
17. Drevets, D. A., B. P. Canono, P. J. Leenen, and P. A. Campbell. 1994. Gentamicin kills intracellular Listeria monocytogenes. Infect. Immun. 62:2222-2228.
18. Edwards, S. W. 1996. The O-2 Generating NADPH Oxidase of Phagocytes: Structure and methods of detection. Methods 9:563-577.
19. Ernst, J. D. 2000. Bacterial inhibition of phagocytosis. Cell Microbiol. 2:379-386.
20. Finlay, B. B., and P. Cossart. 1997. Exploitation of mammalian host cell functions by bacterial pathogens. Science 276:718-725.
21. Garcia, I., A. Pascual, S. Ballesta, and E. J. Perea. 2000. Uptake and intracellular activity of ofloxacin isomers in human phagocytic and non-phagocytic cells. Int. J. Antimicrob. Agents 15:201-205.
22. Gilbert, D. 2000. Aminoglycosides. Churchill Livingstone, Philadelphia, PA.
23. Gordon, C., C. Regamey, and W. M. Kirby. 1972. Comparative clinical pharmacology of amoxicillin and ampicillin administered orally. Antimicrob. Agents Chemother. 1:504-507.
24. Greenbloom, S. L., A. H. Steinhart, and G. R. Greenberg. 1998. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can. J. Gastroenterol. 12:53-56.
25. Guarner, F., F. Casellas, N. Borruel, M. Antolin, S. Videla, J. Vilaseca, and J. R. Malagelada. 2002. Role of microecology in chronic inflammatory bowel diseases. Eur. J. Clin. Nutr. 56(Suppl. 4):S34-S38.
26. High, N., J. Mounier, M. C. Prevost, and P. J. Sansonetti. 1992. IpaB of Shigella flexneri causes entry into epithelial cells and escape from the phagocytic vacuole. EMBO J. 11:1991-1999.
27. Huang, J. S., D. Noack, J. Rae, B. A. Ellis, R. Newbury, A. L. Pong, J. E. Lavine, J. T. Curnutte, and J. Bastian. 2004. Chronic granulomatous disease caused by a deficiency in p47(phox) mimicking Crohn's disease. Clin. Gastroenterol. Hepatol. 2:690-695.
28. Kotlowski, R., C. N. Bernstein, S. Sepehri, and D. O. Krause. 2007. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut 56:669-675.
29. Leiper, K., A. I. Morris, and J. M. Rhodes. 2000. Open label trial of oral clarithromycin in active Crohn's disease. Aliment. Pharmacol. Ther. 14:801-806.
30. Liu, Y., H. J. van Kruiningen, A. B. West, R. W. Cartun, A. Cortot, and J. F. Colombel. 1995. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 108:1396-1404.
31. Lodes, M. J., Y. Cong, C. O. Elson, R. Mohamath, C. J. Landers, S. R. Targan, M. Fort, and R. M. Hershberg. 2004. Bacterial flagellin is a dominant antigen in Crohn disease. J. Clin. Investig. 113:1296-1306.
32. Lohitnavy, M., O. Lohitnavy, K. Sareekan, and W. Chaiyaput. 2003. Average bioequivalence study of clarithromycin tablets in healthy male volunteers. J. Clin. Pharm. Ther. 28:187-190.
33. Marks, D. J., M. W. Harbord, R. MacAllister, F. Z. Rahman, J. Young, B. Al-Lazikani, W. Lees, M. Novelli, S. Bloom, and A. W. Segal. 2006. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 367:668-678.
34. Martin, H. M. 2003. Characterisation of mucosa-associated Escherichia coli in inflammatory bowel disease and colon cancer. Ph.D. thesis. University of Liverpool, Liverpool, United Kingdom.
35. Martin, H. M., B. J. Campbell, C. A. Hart, C. Mpofu, M. Nayar, R. Singh, H. Englyst, H. F. Williams, and J. M. Rhodes. 2004. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 127:80-93.
36. Meconi, S., A. Vercellone, F. Levillain, B. Payre, T. Al Saati, F. Capilla, P. Desreumaux, A. Darfeuille-Michaud, and F. Altare. 2007. Adherent-invasive Escherichia coli isolated from Crohn's disease patients induce granulomas in vitro. Cell Microbiol. 9:1252-1261.
37. Mei, L., S. R. Targan, C. J. Landers, D. Dutridge, A. Ippoliti, E. A. Vasiliauskas, K. A. Papadakis, P. R. Fleshner, J. I. Rotter, and H. Yang. 2006. Familial expression of anti-Escherichia coli outer membrane porin C in relatives of patients with Crohn's disease. Gastroenterology 130:1078-1085.
38. Meyer, A. P., C. Bril-Bazuin, H. Mattie, and P. J. van den Broek. 1993. Uptake of azithromycin by human monocytes and enhanced intracellular antibacterial activity against Staphylococcus aureus. Antimicrob. Agents Chemother. 37:2318-2322.
39. Milatovic, D. 1990. Intraphagocytic activity of erythromycin, roxithromycin and azithromycin. Eur. J. Clin. Microbiol. Infect. Dis. 9:33-35.
40. Nguyen, H. A., J. Grellet, D. Paillard, V. Dubois, C. Quentin, and M. C. Saux. 2006. Factors influencing the intracellular activity of fluoroquinolones: a study using levofloxacin in a Staphylococcus aureus THP-1 monocyte model. J. Antimicrob. Chemother. 57:883-890.
41. Nicolau, D. P. 2001. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection 29(Suppl. 2):11-15.
42. Nuding, S., K. Fellermann, J. Wehkamp, and E. F. Stange. 2007. Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut. 56:1240-1247.
43. O'Brien, D. K., and S. B. Melville. 2004. Effects of Clostridium perfringens alpha-toxin (PLC) and perfringolysin O (PFO) on cytotoxicity to macrophages, on escape from the phagosomes of macrophages, and on persistence of C. perfringens in host tissues. Infect. Immun. 72:5204-5215.
44. Ochs, H. R., D. J. Greenblatt, and H. J. Dengler. 1978. Absorption of oral tetracycline in patients with Billroth-II gastrectomy. J. Pharmacokinet. Biopharm. 6:295-303.
45. Ogawa, M., and C. Sasakawa. 2006. Intracellular survival of Shigella. Cell Microbiol. 8:177-184.
46. Paillard, D., J. Grellet, V. Dubois, M. C. Saux, and C. Quentin. 2002. Discrepancy between uptake and intracellular activity of moxifloxacin in a Staphylococcus aureus-human THP-1 monocytic cell model. Antimicrob. Agents Chemother. 46:288-293.
47. Parkes, M., J. C. Barrett, N. J. Prescott, M. Tremelling, C. A. Anderson, S. A. Fisher, R. G. Roberts, E. R. Nimmo, F. R. Cummings, D. Soars, H. Drummond, C. W. Lees, S. A. Khawaja, R. Bagnall, D. A. Burke, C. E. Todhunter, T. Ahmad, C. M. Onnie, W. McArdle, D. Strachan, G. Bethel, C. Bryan, C. M. Lewis, P. Deloukas, A. Forbes, J. Sanderson, D. P. Jewell, J. Satsangi, J. C. Mansfield, the Wellcome Trust Case Control Consortium, L. Cardon, and C. G. Mathew. 2007. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat. Genet. 39:830-832.
48. Peloquin, C. A., R. Namdar, M. D. Singleton, and D. E. Nix. 1999. Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. Chest 115:12-18.
49. Prantera, C., H. Lochs, M. Campieri, M. L. Scribano, G. C. Sturniolo, F. Castiglione, and M. Cottone. 2006. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment. Pharmacol. Ther. 23:1117-1125.
50. Prantera, C., F. Zannoni, M. L. Scribano, E. Berto, A. Andreoli, A. Kohn, and C. Luzi. 1996. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am. J. Gastroenterol. 91:328-332.
51. Ribera, E., L. Pou, A. F. Sola, F. Campos, R. M. Lopez, I. Ocaña, I. Ruiz, and A. Pahissa. 2001. Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 45:3238-3241.
52. Rioux, J. D., R. J. Xavier, K. D. Taylor, M. S. Silverberg, P. Goyette, A. Huett, T. Green, P. Kuballa, M. M. Barmada, L. W. Datta, Y. Y. Shugart, A. M. Griffiths, S. R. Targan, A. F. Ippoliti, E-J. Bernard, L. Mei, D. L. Nicolae, M. Regueiro, L. P. Schumm, A. H. Steinhart, J. I. Rotter, R. H. Duerr, J. H. Cho, M. J. Daly, and S. R. Brant. 2007. Genome-wide association study identifies new susceptibility loci for Crohn's disease and implicates autophagy in disease pathogenesis. Nat. Genet. 39:596-604.
53. Rodloff, A. C., J. Becker, D. K. Blanchard, T. W. Klein, H. Hahn, and H. Friedman. 1986. Inhibition of macrophage phagocytosis by Bacteroides fragilis in vivo and in vitro. Infect. Immun. 52:488-492.
54. Rodvold, K. A. 1999. Clinical pharmacokinetics of clarithromycin. Clin. Pharmacokinet. 37:385-398.
55. Rutgeerts, P., K. Goboes, M. Peeters, M. Hiele, F. Penninckx, R. Aerts, R. Kerremans, and G. Vantrappen. 1991. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 338:771-774.
56. Rutgeerts, P., M. Hiele, K. Geboes, M. Peeters, F. Penninckx, R. Aerts, and R. Kerremans. 1995. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 108:1617-1621.
57. Rutgeerts, P., G. Van Assche, S. Vermeire, G. D'Haens, F. Baert, M. Noman, I. Aerden, G. De Hertogh, K. Geboes, M. Hiele, A. D'Hoore, and F. Penninckx. 2005. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128:856-861.
58. Ryan, P., R. G. Kelly, G. Lee, J. K. Collins, G. C. O'Sullivan, J. O'Connell, and F. Shanahan. 2004. Bacterial DNA within granulomas of patients with Crohn's disease - detection by laser capture microdissection and PCR. Am. J. Gastroenterol. 99:1539-1543.
59. Rybak, M. J. 2006. Pharmacodynamics: relation to antimicrobial resistance. Am. J. Med. 119:S37-S44; discussion S62-S70.
60. Sansonetti, P. J., and A. Phalipon. 1999. M cells as ports of entry for enteroinvasive pathogens: mechanisms of interaction, consequences for the disease process. Semin. Immunol. 11:193-203.
61. Saravolatz, L., O. Manzor, J. Pawlak, and B. Belian. 2005. Antimicrobial activity and a comparison of published pharmacodynamics of gemifloxacin and eight fluoroquinolones against Streptococcus pneumoniae. Int. J. Antimicrob. Agents. 26:81-84.
62. Sasaki, M., S. V. Sitaraman, B. A. Babbin, P. Gerner-Smidt, E. M. Ribot, N. Garrett, J. A. Alpern, A. Akyildiz, A. L. Theiss, A. Nusrat, and J.-M. A. Klapproth. 2007. Invasive Escherichia coli are a feature of Crohn's disease. Lab. Investig. 87:1042-1054. doi:10.1038/labinvest. 3700661.
63. Shafran, I., L. Kugler, F. A. El-Zaatari, S. A. Naser, and J. Sandoval. 2002. Open clinical trial of rifabutin and clarithromycin therapy in Crohn's disease. Dig. Liver Dis. 34:22-28.
64. Sitaraman, S. V., J. M. Klapproth, D. A. Moore, 3rd, C. Landers, S. Targan, I. R. Williams, and A. T. Gewirtz. 2005. Elevated flagellin-specific immunoglobulins in Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol. 288:G403-G406.
65. Smythies, L. E., M. Sellers, R. H. Clements, M. Mosteller-Barnum, G. Meng, W. H. Benjamin, J. M. Orenstein, and P. D. Smith. 2005. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J. Clin. Investig. 115:66-75.
66. Steinhart, A. H., B. G. Feagan, C. J. Wong, M. Vandervoort, S. Mikolainis, K. Croitoru, E. Seidman, D. J. Leddin, A. Bitton, E. Drouin, A. Cohen, and G. R. Greenberg. 2002. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 123:33-40.
67. Sturgill, M. G., J. R. Seibold, S. E. Boruchoff, K. C. Yeh, H. Haddix, and P. Deutsch. 1999. Trimethoprim/sulfamethoxazole does not affect the steadystate disposition of indinavir. J. Clin. Pharmacol. 39:1077-1084.
68. Sutherland, L., J. Singleton, J. Sessions, S. Hanauer, E. Krawitt, G. Rankin, R. Summers, H. Mekhjian, N. Greenberger, M. Kelly, et al. 1991. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 32:1071-1075.
69. Swidsinski, A., A. Ladhoff, A. Pernthaler, S. Swidsinski, V. Loening-Baucke, M. Ortner, J. Weber, U. Hoffmann, S. Schreiber, M. Dietel, and H. Lochs. 2002. Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44-54.
70. Swidsinski, A., J. Weber, V. Loening-Baucke, L. P. Hale, and H. Lochs. 2005. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J. Clin. Microbiol. 43:3380-3389.
71. Wehkamp, J., N. H. Salzman, E. Porter, S. Nuding, M. Weichenthal, R. E. Petras, B. Shen, E. Schaeffeler, M. Schwab, R. Linzmeier, R. W. Feathers, H. Chu, H. Lima, Jr., K. Fellermann, T. Ganz, E. F. Stange, and C. L. Bevins. 2005. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc. Natl. Acad. Sci. USA 102:18129-18134.